Targeted radionuclide therapy: a historical and personal review
SJ Goldsmith - Seminars in Nuclear Medicine, 2020 - Elsevier
… This review traces the development of targeted radionuclide therapy (TRT) (the Magic
Bullet) from the discovery of radioactivity in nature and the subsequent discovery of artificial …
Bullet) from the discovery of radioactivity in nature and the subsequent discovery of artificial …
Targeted radionuclide therapy of prostate cancer—from basic research to clinical perspectives
M Czerwińska, A Bilewicz, M Kruszewski… - Molecules, 2020 - mdpi.com
… -targeting ligands labeled with radionuclides have been evaluated in several preclinical and
clinical … are three types of radiation that can be used for targeted radionuclide therapy: β − -…
clinical … are three types of radiation that can be used for targeted radionuclide therapy: β − -…
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
J Sun, Z Huangfu, J Yang, G Wang, K Hu, M Gao… - Advanced Drug Delivery …, 2022 - Elsevier
… -guided targeted radionuclide therapy for different tumors such as advanced prostate cancer
… and their preclinical and clinical results, and further discuss about challenges and future …
… and their preclinical and clinical results, and further discuss about challenges and future …
Combination radionuclide therapy: a new paradigm
SK Suman, S Subramanian, A Mukherjee - Nuclear Medicine and Biology, 2021 - Elsevier
… radionuclide therapy, different holistic combinations of MRT agents with radiosensitizers
targeting … as external beam radiation therapy and carbon ion radiation therapy to enhance the …
targeting … as external beam radiation therapy and carbon ion radiation therapy to enhance the …
Targeted radionuclide therapy: an evolution toward precision cancer treatment
H Jadvar - American Journal of Roentgenology, 2017 - Am Roentgen Ray Soc
… This article reviews recent developments in targeted radionuclide therapy (TRT) approaches
directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-…
directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-…
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
T Al-Toubah, J Strosberg… - Frontiers in …, 2023 - frontiersin.org
… Targeted radionuclide therapy plays an increasingly … advances the therapeutic landscape
for patients with these diseases. With increasing FDA-approved therapies and advances in the …
for patients with these diseases. With increasing FDA-approved therapies and advances in the …
Advances in peptide receptor radionuclide therapy
A Sabet, HJ Biersack, S Ezziddin - Seminars in nuclear medicine, 2016 - Elsevier
… Because of the high linear energy transfer rate and short tissue-penetration range, alpha
particles could be potentially very suitable for targeted radionuclide treatment with an extremely …
particles could be potentially very suitable for targeted radionuclide treatment with an extremely …
Radionuclides for targeted therapy: physical properties
C Stokke, M Kvassheim, J Blakkisrud - Molecules, 2022 - mdpi.com
… This review focuses on the physical characteristics of radionuclides that are relevant for
radionuclide therapy, such as linear energy transfer, relative biological effectiveness, range, half-…
radionuclide therapy, such as linear energy transfer, relative biological effectiveness, range, half-…
New radionuclides and technological advances in SPECT and PET scanners
… of the same targeting agents as are subsequently used for therapeutic applications [46,52]. …
targeted radionuclide therapy with Lu-177 and Y-90. The exact matched therapeutic …
targeted radionuclide therapy with Lu-177 and Y-90. The exact matched therapeutic …
Clinical perspectives of theranostics
S Okamoto, T Shiga, N Tamaki - Molecules, 2021 - mdpi.com
… been focused upon. Theranostics will become an ever-increasing part of clinical nuclear
medicine. This will lead to adaptation of personalized molecular targeted radionuclide therapy …
medicine. This will lead to adaptation of personalized molecular targeted radionuclide therapy …